Tempus AI与Predicta Biosciences今日宣布建立战略合作关系，双方将共同推动超灵敏全基因组测序技术在血液系统恶性肿瘤及微小残留病变监测领域的应用普及。
此次合作旨在为生命科学研究机构提供更先进的基因组分析工具，通过整合Tempus的人工智能平台与Predicta Biosciences的尖端测序技术，显著提升对血液肿瘤相关基因变异的检测灵敏度。
该超灵敏全基因组测序方案能够精准识别传统方法难以发现的低频突变，为临床医生和研究人员提供更全面的基因组信息，助力血液恶性肿瘤的精准诊断和治疗效果评估。
双方表示，这一合作将加速新型生物标志物的发现进程，推动个体化医疗在血液肿瘤领域的发展，最终为患者带来更精准的治疗方案和更好的预后管理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.